ReproHepato™: The world’s first commercial hiPSC-hepatocytes

Product Classification : hiPSC-HepatocytesResearch Theme : Drug Effect Test, Pharmacological Effectiveness Test, Drug metabolism, Hepatitis, Safety Test, Toxicology test

ReproHepato™: The world’s first commercial hiPSC-hepatocytes

Constantly available human hepatocytes with robust enzymatic activity

  • Robust CYP activity
  • Expression of transporters (NTCP and OATP1B1, etc.)
  • Longer retention of CYP activity
  • Hepatotoxic response similar to primary hepatocytes
  • CYP induction assay and hepatotoxicity assay services available in Japan

ReproCELL has launched ReproHepato™ – constantly available, high-quality, and fully-differentiated human hepatocytes derived from iPS cells that are commercialized for the first time in the world..

The cells provided are differentiated hepatocytes. After six days in culture using Maintenance Medium included in the kit, the cells are ready for CYP assay.*: The cells should be kept in liquid nitrogen.

Data

High-purity CYP-positive hepatocytes from human iPS cells

ReproHepato™ cells have typical human hepatocyte-like morphology and characteristics.The expression of key hepatic
components such as CYP3A4, HNF4a, E-cadherin, and albumin in high percentages of ReproHepato™ cells is indicative of the high purity of these cells.
(Click to enlarge the pictures)

Bright field image

Bright field image

PAS staining showing glycogen storage

PAS staining showing glycogen storage

Immunostaining for E-cadherin (green) and HNF4a (red)

Immunostaining for E-cadherin (green)
and HNF4a (red)

FACS analysis of CYP3A4-positive cells

FACS analysis of CYP3A4-positive cells

FACS analysis of albumin-positive cells

FACS analysis of albumin-positive cells

Robust CYP activity and induction capability (Assay service available in Japan)

CYP3A4 activity is modulated by typical inducers and inhibitors in a dose-dependent manner, as in the case of primary hepatocytes. Activity and inducibility of other CYPs (1A2/2C9/2C19) is also observed at levels comparable to those of primary hepatocytes.
CYP2D6 activity is also observed in the upcoming version of ReproHepato, which is under development now.

ReproCELL offers a contract CYP assay service using in Japan ReproHepato. Please contact ReproCELL for the details of CYP assay service.

Small lot-to-lot variation; more consistent results

Compared to primary hepatocytes, ReproHepato? hepatocytes show less lot-to-lot variation in CYP activity and inducibility.

rifampicin-induced CYP3A4 activity measured by luminescence method

change of CYP3A4 activity(ratio of the values in the figure on the left)

Long life in culture

ReproHepato can be cultured for a long time in vitro while retaining hepatic functions. Contact ReproCELL for the preliminary results.

Presentations

  • Society for Biomolecular Sciences(SBS), 14th AnnualConference & Exhibition 2008 (St. Louis), poster session, April 2008.
  • IBC Asia's 4th Annual Stem Cells Asia Congress (Singapore), oral session, June 2008.
  • ELRIG and SBS Present: Drug Discovery (UK) poster session, September 2008.
  • Advances in Stem Cell Discoveries (San Francisco) oral session, September 2008.
  • Stem Cells: Drug Discovery and Therapeutics (London) oral session, February 2008.
  • Society for Biomolecular Science 15th Annual Conference (France), poster session, Best Poster 2009 Award-winning, April 2009.
  • Stem Cells and Regenerative Medicine Europe (UK), September 2009, Best Poster 2009 Award-winning.
  • MipTec Conference 2009, October 13-15, Basel Invited Lecture.
  • The 74th Annual Scientific Meeting of the Japanese Circulation Society(Kyoto), March 2010.
  • The 130th The Pharmaceutical Society of Japan(Okayama), March 2010.
  • The Society of Toxicology (SOT) 51st Annual Meeting (CA, USA), poster session, March 2012.
  • Safety Pharmacology Society (SPS), 13th annual meeting 2013 (Rotterdam, Netherlands), poster session, September 2013.
  • Automated Patch-Clamp systems and Ion Channel Expressing Cells 2013 (Tokyo), Verbal presentation 2013 Nov.
  • The 7th Takeda Science Foundation Symposium (Osaka), Poster presentation 2014 Jan.
  • Inamura, Mitsuru and Yokoyama, Chikafumi. "Human iPS cell-derived hepatocytes for drug screening." Regenerative Medicine (2013)
  • Scott, Clay W., Matthew F. Peters, and Yvonne P. Dragan. "Human induced pluripotent stem cells and their use in drug discovery for toxicity testing." Toxicology letters 219.1 (2013): 49-58.

Publications

  • Inamura, Mitsuru and Yokoyama, Chikafumi. “Human iPS cell-derived hepatocytes for drug screening.” Regenerative Medicine (2013)
  • Scott, Clay W., Matthew F. Peters, and Yvonne P. Dragan. “Human induced pluripotent stem cells and their use in drug discovery for toxicity testing.” Toxicology letters 219.1 (2013): 49-58.

Product list

Catalog No. Product Price
RCDH001N ReproHepato™ Ask
RCDH101 ReproHepato Culture Medium™ Ask
RCDH301 ReproHepato Assay Medium™ Ask

Contents & storage condition

RCDH001N ReproHepato™: contents

  • human iPS cell-derived heptocytes
    8.25 x 106 cells (1 vial)
    (frozen cells, for plating one whole 96-well plate)

RCDH101
ReproHepato Culture Medium™

  • ReproHepato Culture Medium (80 mL)
  • ReproHepato Culture Medium Supplement (400 μL)

RCDH301
ReproHepato Assay Medium™

  • ReproHepato Assay Medium (30 mL)
  • ReproHepato Assay Medium Supplement (300 μL)

The cells provided are differentiated hepatocytes. After six days in culture using Maintenance Medium included in the kit, the cells are ready for CYP assay.

Storage condition Cells: LN2
Use as soon as possible.
Other reagents: -20 degC
Shipping Cell:dryshipper
Other reagents:dryice

Related Products

Catalog No. Product Price
RCESDH401 CYP Assay Service Ask
Hepatotoxicity assay service Ask